T-cells are central in the protection against infections and cancer. With the help of TCRs (T-cell receptors), cells recognize foreign invaders and tumor cells.
“It was previously unknown how variable human TCR genes are,” said Gunilla Karlsson Hedestam, professor at the department of microbiology, tumor and cell biology at Karolinska Institutet in Sweden, and the study’s lead author.
Using deep sequencing of blood samples, the researchers examined TCR genes in 45 people originating from sub-Saharan Africa, East Asia, South Asia and Europe. The researchers showed that these genes vary greatly between different individuals and population groups. The results were confirmed by analyses of several thousand additional cases from the 1000 Genomes project.
“We found that every individual, other than identical twins, has a unique set of TCR gene variants. These differences reveal possible mechanisms underlying the wide range of responses to infections and vaccines that we observe at the population level,” said Martin Corcoran, the first author of the study.
“We discovered 175 new gene variants, which doubles the number of known TCR gene variants. An unexpected and surprising finding is that certain gene variants originate from Neanderthals and one of these is present in up to 20% of modern humans in Europe and Asia.”
Gunilla Karlsson Hedestam said the variation in these TCR genes cannot be detected with the standard methods used in whole genome sequencing, but with the development of specialized deep sequencing methods and analysis software that allow highly precise definition of B- and T-cell receptor genes, this is now possible.
TCR gene variation: therapeutic development implications
“As these genes are among the most variable in our genome, the results also provide new information about how our immune system has developed over the course of history,” Corcoran said.
“We are particularly interested in uncovering the function of the TCR variants we have inherited from Neanderthal ancestors. The frequency of these variants in modern humans suggests an advantageous function in our biology and we are keen to understand this.”
The findings and the new TCR gene database the researchers now publish can be of great importance in the development of new therapeutic approaches in the future.
“Understanding human genetics is fundamental for the development of targeted treatments. The methods described in the study provide new opportunities, not the least in the cancer field where T-cells are central to several promising forms of immunotherapy,” said Karlsson Hedestam.
The results can also shed light on other areas of research.
“The findings can lead to the development of new diagnostics and therapies in a range of medical disciplines, including precision medicine,” Karlsson Hedestam added.
“We are now investigating the functional significance of several of the newly discovered gene variants and how this variation impacts our T-cell responses. We are also planning extended studies involving large groups of individuals to examine the role of TCR gene variation in diseases we know involve T cells, such as infectious diseases, cancer, and autoimmune disorders.”
Partnering 2030: The Biotech Perspective 2023